Related Experiment Video

Updated: Jun 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

Howard L Kaufman1, Steven D Bines

  • 1The Tumor Immunology Laboratory & Department of General Surgery, Rush University Medical Center, Chicago, IL 60612, USA. howard_l_kaufman@rush.edu

Future Oncology (London, England)
|June 10, 2010
PubMed

Insights

Oncolytic herpes simplex virus (Oncovex(GM-CSF)) shows promise for advanced melanoma, with a 28% response rate in Phase II trials. This therapy works by directly killing tumors and stimulating an immune response.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Advanced melanoma lacks effective treatments.
  • Oncolytic viruses offer a novel therapeutic approach.

Purpose of the Study:

  • To evaluate the efficacy and safety of Oncovex(GM-CSF) in advanced melanoma.
  • To investigate the dual mechanism of action of Oncovex(GM-CSF).

Main Methods:

  • Phase II clinical trial of direct injection of Oncovex(GM-CSF) into melanoma lesions.
  • Prospective, randomized Phase III clinical trial (OPTIM trial) initiated for unresectable Stage IIIb/c and Stage IV melanoma.

Main Results:

  • Phase II trial demonstrated a 28% objective response rate.
  • Observed regression in both injected and noninjected lesions, indicating a dual mechanism.

Conclusions:

  • Oncovex(GM-CSF) exhibits a dual mechanism of action: direct oncolysis and immune-mediated anti-tumor effects.
  • Preliminary results support further investigation in a Phase III trial for advanced melanoma treatment.

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...